Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRX003 SAD study in healthy subjects
NCT02458677Phase 1Completed
- Sponsor
- Prothena Corporation
- Start
- May 2015
- Primary completion
- Feb 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in psoriasis comparing PRX003 with Placebo (2 arms). Primary endpoints: Safety and tolerability as determined by number of subjects with adverse events at 3 months, Determination of pharmacokinetics parameters-(Cmax) at 3 months and 6 more. Started May 2015; status: completed.
02
Drugs
Imaprelimab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT02458677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02458677.